- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05671679
Supporting Meal Management in Type 1 Diabetes (SUMMIT1)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diet and physical activity are critically important in the lifestyle of people with type 1 diabetes. When diagnosed with the disease, people with type 1 diabetes are educated about nutritional goals and how to estimate nutritional content of food. Carbohydrates are the food component with the greatest impact on blood glucose levels and typical sources in the diet include starches, some vegetables, fruits, dairy products and sugars . Thus, people with type 1 diabetes are primarily being trained to estimate the carbohydrate content of food, a task that is also referred to as carbohydrate counting. Different methods can be used to count carbohydrate in food and drink. These include reading the nutritional labels, consulting reference books or websites, carrying a database on a personal digital assistant or using exchange tables which provides the carbohydrate content for typical serving sizes (e.g. 1 slice of bread). While nutritional information can be accessed through the above mentioned methods, the quantification of the portion sizes (if not indicated on the food package) requires the additional use of scale or measuring vessel. Given the required effort and time investment related to these methods, the great majority of people with type 1 diabetes count carbohydrates by visual estimation and experience. As a consequence, people's estimate often deviate substantially from ground truth values and average carbohydrate estimation errors reported in the literature are 20% or higher.
Of note, more than 60% of individuals with diabetes report having trouble with carbohydrate counting, despite their awareness on its importance . Even in patients who are confident in applying carbohydrate counting, the daily task is perceived as major burden of diabetes self-management.
Since carbohydrate counting is particularly demanding when eating fresh, non-packaged foods, a concerning trend towards unhealthy dietary choices with preference of prepackaged foods (with accessible nutrition facts) over whole foods is increasingly observed in people with type 1 diabetes. This is paralleled by an increasing prevalence of overweight and obesity in the type 1 diabetes population.
Thus, even with the latest hybrid closed-loop insulin delivery technologies, adequate nutrition knowledge remains a cornerstone for satisfactory glucose control, metabolic health, and prevention of diabetes-related complications and comorbidities.
With the development of new technologies embedded in modern smartphones (i.e. depth sensors), image-based methods to support food assessment have become widely available. Of particular use is the employment of well-established computer vision methodologies to estimate the quantity of food. When combined with food-recognition technologies and information from nutritional databases, a proposition of the nutritional content (e.g. carbohydrates, fat, proteins, fibres) can be made to the user on the basis of captured images and obviates the need for error prone visual estimations and mental calculations. Several such applications have become available and can support monitoring the diet as part of lifestyle management.
Insights from a recent online survey suggest that a high proportion of people with type 1 diabetes believe that such new technologies for meal management could facilitate their daily self-management and would be interested in using such technology. Moreover, according to a recent study, such digital tools may promote diabetes education and food literacy which may particularly benefit those with a lower education level and with a history of depression.
Amongst several options (e.g. Foodvisor, Calorie-Mamma, Lifesum) for image-based food tracking and analysis, SNAQ is one of the most commonly used app in people with type 1 diabetes. Up to date, more than 40000 users have downloaded the SNAQ app in their phones, of which 2,500 are living in Switzerland.
The investigators have previously demonstrated that the system estimates the macronutrient content of real meals with satisfying accuracy.
However, evidence with regards to the effect of the food analysis on daily self-management of people with type 1 diabetes (e.g. glucose control, meal patterns, perceived benefits) is currently lacking. The investigators therefore aim to address these aspects in a randomized-controlled study contrasting the use of the SNAQ app with people's traditional meal management techniques.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
BE
-
Bern, BE, Switzerland, 3010
- Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent
- Adults (aged 18 years or older)
- Type 1 diabetes (as defined by World Health Organization (WHO) for at least 12 month)
- Current use of a commercial hybrid closed-loop system
- HbA1c≤12% (measured within the past 3 months)
- Willing to use the SNAQ app on a daily basis for over 3 weeks
- The participant is willing to follow study specific instructions and share their treatment data with the study team
Exclusion Criteria:
- Any physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results
- Previous use of SNAQ app for more than 5 days within the past 3 months
- Self-reported pregnancy, planed pregnancy within next 3 months or breast-feeding
- Severe visual impairment
- Severe hearing impairment
- Lack of reliable telephone facility for contact
- Concomitant participation in another trial that interferes with the normal conduct of the study and interpretation of the study results
- Participant not proficient in German
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
The intervention group will use SNAQ app for the first 3 weeks (baseline to V1) of the study.
|
SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image.
The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g.
foods, ingredients, sauces, herbs or seasonings).
Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database.
Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function.
The user can always adapt proposed nutritional contents at their own discretion.
Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices.
The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
|
|
Active Comparator: Control
The control group will continue estimating the carbohydrate count using their traditional methods for the first three weeks of the study (baseline to V1).
|
Patients will follow their traditional methods of carbohydrate counting during the control period.
In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of time with sensor glucose in the target range
Time Frame: 3-week intervention period (Day 1 to Day 21)
|
Percentage of time with sensor glucose in the target range between 3.9 to 10.0mmol/L, %
|
3-week intervention period (Day 1 to Day 21)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of time with sensor glucose in hyperglycaemia
Time Frame: 3-week intervention period (Day 1 to Day 21)
|
Percentage of time with sensor glucose in the target range above 10.0mmol/L, %
|
3-week intervention period (Day 1 to Day 21)
|
|
Percentage of time with sensor glucose in hypoglycaemia
Time Frame: 3-week intervention period (Day 1 to Day 21)
|
Percentage of time with sensor glucose in the target range below 3.9 mmol/L, %
|
3-week intervention period (Day 1 to Day 21)
|
|
Percentage of postprandial time with sensor glucose in target range
Time Frame: 3-week intervention period (Day 1 to Day 21)
|
Percentage of postprandial time with sensor glucose in target range between 3.9 to 10.0 mmol/L
|
3-week intervention period (Day 1 to Day 21)
|
|
Percentage of postprandial time with sensor glucose in hyperglycaemia
Time Frame: 3-week intervention period (Day 1 to Day 21)
|
Percentage of postprandial time with sensor glucose in the target range above 10.0mmol/L, %
|
3-week intervention period (Day 1 to Day 21)
|
|
Percentage of postprandial time with sensor glucose in hypoglycaemia
Time Frame: 3-week intervention period (Day 1 to Day 21)
|
Percentage of postprandial time with sensor glucose in the target range below 3.9 mmol/L, %
|
3-week intervention period (Day 1 to Day 21)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lia Bally, MD PhD, UDEM Inselspital, University Hospital of Berne, and University Berne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SUMMIT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...Not yet recruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes Mellitus
-
GentiBio, IncRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes (T1D)United States
-
Stanford UniversityUniversity College Dublin; The Leona M. and Harry B. Helmsley Charitable TrustNot yet recruitingType 1 Diabetes (T1D) | Type 1 Diabetes Mellitus (T1DM) | Exercise Physiology | Type 1 Diabetes MellitisUnited States
-
Dasman Diabetes InstituteRecruitingType 1 Diabetes (T1D) | Type 1 Diabetes Mellitus (T1DM)Kuwait
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Insulet CorporationNot yet recruitingType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes (DM)New Zealand
Clinical Trials on SNAQ app
-
University of VictoriaRecruiting
-
Hypnalgesics, LLCTufts UniversityCompletedDental Anxiety | Opioid Use | Drug Use | Dental PainUnited States
-
Barbara Ann Karmanos Cancer InstituteCompletedCancer | Financial Toxicity | Question Prompt ListUnited States
-
University of California, San FranciscoConquer Cancer FoundationCompletedProstate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Chang Gung UniversityChang Gung Memorial HospitalRecruiting
-
New York UniversityJoon, Inc.RecruitingDepression | Stress | Anxiety | Executive Dysfunction | Behavior, Child | Disruptive Behavior | Attention-deficitUnited States
-
University of Sao PauloNot yet recruitingPostpartum Depression
-
Emory UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Florida Atlantic UniversityCompletedHealth BehaviorUnited States
-
Kent State UniversitySumma Health SystemUnknown